Overview

Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

Status:
Completed
Trial end date:
2018-07-25
Target enrollment:
Participant gender:
Summary
Healthy male and female volunteers without asthma will be recruited to enroll in a single dose 3-way crossover study of the safety and pharmacokinetics of albuterol when administered using the Halix (TM) albuterol unit dose disposable dry powder inhaler (DPI) and the albuterol HFA (hydrofluoroalkane) MDI inhaler.
Phase:
Phase 1
Details
Lead Sponsor:
Concentrx Pharmaceuticals, Inc.
Collaborators:
Kramer Consulting, LLC
PharPoint Research, Inc.
Treatments:
Albuterol